PegFilgrastim Injection– A Long Lasting RhG-CSF， CAS No.: 208265-92-3，Bulk and Injection (PFS): 6mg in 0.6ml

Introduction

PegFilgrastim Injection is a long-lasting RhG-CSF drug that leverages the power of biotechnology to enhance immune function in patients. The drug comes in two forms, bulk and injection (PFS), and features a concentration of 6mg in 0.6ml. As a Chinese manufacturer, we are proud to provide quality products that meet international standards and represent the next generation of healthcare solutions.

Key Product Features

PegFilgrastim Injection is derived from granulocyte colony-stimulating factor, a natural protein that plays a crucial role in the production and maintenance of white blood cells in the body. By targeting the bone marrow and stimulating the production of these cells, the drug can enhance the body's immune response and improve patient outcomes following chemotherapy, radiation therapy, or bone marrow transplantation.

The main advantage of PegFilgrastim Injection over conventional forms of RhG-CSF is its extended half-life. By modifying the protein with polyethylene glycol, the drug can remain in the bloodstream for longer periods, reducing the need for daily injections and improving patient convenience. Additionally, the modified protein is less immunogenic, resulting in fewer adverse reactions and improved safety.

Another key feature of PegFilgrastim Injection is its versatility. The drug can be used in a variety of therapeutic applications, including the treatment of neutropenia in cancer patients, the mobilization of hematopoietic stem cells for bone marrow transplantation, and the prevention of febrile neutropenia in patients undergoing chemotherapy.

Quality and Compliance

At our manufacturing facility in China, we adhere to strict quality control standards to ensure that all of our products meet or exceed international regulations. We maintain active partnerships with third-party testing and accreditation organizations to ensure that our products are safe, effective, and reliable.

We adhere to the most stringent quality control standards at each stage of the production process, from raw material sourcing to final packaging and distribution. Our team of experts performs comprehensive testing on all batches of PegFilgrastim Injection to ensure that they meet or exceed the purity, potency, and safety requirements set forth by regulatory organizations around the world.

Logistics and Delivery

At our manufacturing facility in China, we maintain a large inventory of PegFilgrastim Injection to ensure that we can meet the demand of our customers in a timely and efficient manner. Our logistical capabilities include air and sea freight shipping options to ensure that our products can reach customers in every corner of the globe.

We understand the importance of timely delivery and strive to provide our customers with a reliable and fast shipping solution. Our experienced logistics team works closely with shipping companies and customs agents to ensure that our products are delivered on time and in compliance with all relevant regulations.

Conclusion

PegFilgrastim Injection is an innovative RhG-CSF product that offers a range of benefits over conventional forms of the drug. As a manufacturer located in China, we are proud to offer this advanced healthcare solution to merchants around the world. With our commitment to quality, compliance, and logistics, we are confident that we can deliver a high-quality PegFilgrastim Injection product that meets the needs of our customers and improves patient outcomes.

DESCRIPTION

Pegfilgrastim is a covalent conjugate of recombinant methionyl human G-CSF (filgrastim) and monomethoxypolyethylene glycol. Filgrastim is a water soluble 175 amino acid protein with a molecular weight of approximately 19 kilodaltons (kD). Filgrastim is obtained from the bacterial fermentation of a strain of E coli transformed with a genetically engineered plasmid containing the human G-CSF gene. To produce pegfilgrastim, a 20 kD monomethoxy polyethylene glycol molecule is covalently bound to the N-terminal methionyl residue of filgrastim. The average molecular weight of pegfilgrastim is approximately 39 kD. Neulasta is provided in two presentations:

Neulasta for manual subcutaneous injection is supplied in 0.6 mL prefilled syringes. The prefilled syringe does not bear graduation marks and is designed to deliver the entire contents of the syringe (6 mg/0.6 mL).

On-body injector (OBI) for Neulasta is supplied with a prefilled syringe containing 0.64 mL of Neulasta in solution that delivers 0.6 mL of Neulasta in solution when used with the OBI for Neulasta. The syringe does not bear graduation marks and is only to be used with the OBI for Neulasta.

The delivered 0.6 mL dose from either the prefilled syringe for manual subcutaneous injection or the OBI for Neulasta contains 6 mg pegfilgrastim (based on protein weight) in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), polysorbate 20 (0.02 mg), sodium (0.02 mg), and sorbitol (30 mg) in Water for Injection, USP.

Mechanism of Action

Pegfilgrastim is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Pharmacodynamics

Animal data and clinical data in humans suggest a correlation between pegfilgrastim exposure and the duration of severe neutropenia as a predictor of efficacy. Selection of the dosing regimen of Neulasta is based on reducing the duration of severe neutropenia.

Name: Pegfilgrastim

Pegfilgrastim (pegfilgrastim) is a colony-stimulating factor, a man-made form of a protein that stimulates the growth of white blood cells, used to decrease the incidence of infection, by treating neutropenia, a lack of certain white blood cells caused by receiving cancer chemotherapy.

Dosage: Injection

Specification

6mg: 6ml

Indications

Patients With Cancer Receiving Myelosuppressive Chemotherapy

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia .

Hangzhou Jiuyuan is a top-biotech joint venture specializing in the research, development, manufacture, and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993. It has gene engineering workshops, injection workshops, pharmaceutical API workshops, and other sections including the quality management department, warehouse, engineering department, etc., all of which are built according to GMP requirements. Jiuyuan is equipped with advanced production and analysis instruments like chromatography systems, HPLC, and capillary electrophoresis. We offer high-quality products and comprehensive sales services, please contact us.

Focus on the enterprise purpose of "Take gene engineering as orientation, Render service to human health", the company adheres to serving the Chinese market as the main body and supporting some foreign markets as the auxiliary. Jiuyuan Marketing cultivates a professional, dedicated, and enterprising pharmaceutical service team establishes a stable, credible, and efficient pharmaceutical service network, and focuses on timely delivery of high-quality pharmaceutical products which are the crystallization of scientific research, quality control, and production, to the patients in urgent need, and efficient operation for safe, effective and economic use.

We have been pursuing to improve professional pharmaceutical service skills, expand the radiation capacity of the pharmaceutical service network, and it is our constant pursuit to make Jiuyuan Pharmaceutical products and medical devices to serve human health.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

FAQ

Q: When can I get the price?

A: Usually we quote within 8 hours after we get your inquiry.

Q: What's your MOQ?

A: If we have the products in stock, it will be no MOQ. If we need to produce, we can discuss the MOQ according to customer's exact situation.

Q: How long is your delivery time?

A: The general delivery time is 30-45 days after receiving your order confirmation. if we have the goods in stock, it will only take 1-2 days.

Q: Do you provide sample? Is it free?

A: If the sample is low value, we will provide the free sample with freight collect. But for some high value samples, we need to collect the sample charge.

Q: What is your term of payment?

A: 30% down payment before producing and 70% balance payment before shipping.

Our Services

1. Good knowledge on different market can meet special requirements.

2. Real manufacturer with our own factory located in China

3. Strong professional technical team ensure to produce the top quality products.

4. Special cost control system ensure to provide the most favorable price.

5. Rich experience on drug.

Why choose us?

• Our company is a leading supplier and manufacturer of Oncology Injection products with competitive pricing.
• The company focuses on service innovation and provides diversified, personalized and professional value-added extended services.
• If you're looking for reliable and high-quality Oncology Injection products, our Chinese factory is your best choice.
• To achieve the pursuit of high quality management by scientific and technological innovation is the eternal goal of the company's sustainable development.
• We use premium quality raw materials to produce Oncology Injection products that are safe, reliable, and long-lasting.
• Our company uses the open economic environment to carry out more international exchanges and cooperation, introduces advanced technology, and promotes its PegFilgrastim Injection– A Long Lasting RhG-CSF， CAS No.: 208265-92-3，Bulk and Injection (PFS): 6mg in 0.6ml to the international market.
• We are committed to achieving customer satisfaction and work closely with our clients to understand their unique needs and preferences.
• With the adjustment of industrial structure, the continuous innovation of technology and the continuous technological progress of enterprises, more and more attention has been paid to high skilled talents in our company.
• Our Chinese factory offers fast and efficient shipping services for our Oncology Injection products, ensuring timely and safe deliveries.
• Our company has self-built modern warehousing and rapid distribution center, introduced international advanced production equipment and management system, established a professional PegFilgrastim Injection– A Long Lasting RhG-CSF， CAS No.: 208265-92-3，Bulk and Injection (PFS): 6mg in 0.6ml comprehensive industrial chain, and provided multiple styles of PegFilgrastim Injection– A Long Lasting RhG-CSF， CAS No.: 208265-92-3，Bulk and Injection (PFS): 6mg in 0.6ml and supporting products to meet the needs of millions of consumers around the world.

Hot Tags: pegfilgrastim injection– a long lasting rhg-csf， cas no.: 208265-92-3，bulk and injection (pfs): 6mg in 0.6ml, China pegfilgrastim injection– a long lasting rhg-csf， cas no.: 208265-92-3，bulk and injection (pfs): 6mg in 0.6ml manufacturers, suppliers, factory, tumor medicine injection, rhG-CSF injection 300µg/unit, tumor manufacturing injection, cancer manufacturing injection, anti cancer export injection, oncology solution injection